Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington’s disease mouse modelHuman Molecular Genetics.  28:487-500. 2019
2014 Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's diseaseNature Medicine.  20:536-541. 2014
2013 α-synuclein overexpression represses 14-3-3θ transcriptionJournal of Molecular Neuroscience.  51:1000-1009. 2013
2013 Enhanced Ca2+-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse modelNeurobiology of Disease.  58:192-199. 2013
2012 Network organization of the huntingtin proteomic interactome in mammalian brainNeuron.  75:41-57. 2012
2011 Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in HPSA/TAU P301L double-transgenic miceHuman Molecular Genetics.  20:1820-1833. 2011
2011 Identifying polyglutamine protein species in situ that best predict neurodegenerationNature Chemical Biology.  7:925-934. 2011
2008 Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD MiceJournal of Neuroscience.  28:6182-6195. 2008
2003 Mutations in deadly seven/notch1a Reveal Developmental Plasticity in the Escape Response CircuitJournal of Neuroscience.  23:8159-8166. 2003
2001 Zebrafish deadly seven Functions in NeurogenesisDevelopmental Biology.  237:306-323. 2001

Chapter

Year Title Altmetric
2014 Basal Ganglia Disorders 2014
2014 The role of astrocytes in Huntington's disease.  213-229. 2014
2013 Basal Ganglia Disorders.  1-39. 2013

Education And Training

  • Doctor of Philosophy in Molecular Biology, Ohio State University System : Columbus 2003
  • University of California Los Angeles Semel Institute of Neuroscience and Human Behavior, Postdoctoral Fellowship 2008
  • Full Name

  • Michelle Gray